Literature DB >> 29458111

PPARδ modulation rescues mitochondrial fatty acid oxidation defects in the mdx model of muscular dystrophy.

Eric L Bell1, Robert W Shine2, Peter Dwyer2, Lyndsay Olson2, Jennifer Truong2, Ross Fredenburg2, Matthew Goddeeris2, Dominique Stickens2, Effie Tozzo2.   

Abstract

Duchenne muscular dystrophy (DMD) is a recessive, fatal X-linked disease that is characterized by progressive skeletal muscle wasting due to the absence of dystrophin, which is an a essential protein that bridges the inner cytoskeleton and extra-cellular matrix. This study set out to characterize the mitochondria in primary muscle satellite cell derived myoblasts from mdx mice and wild type control mice. Compared to wild type derived cells the mdx derived cells have reduced mitochondrial bioenergetics and have fewer mitochondria. Here, we demonstrate that a novel PPARδ modulator improves mitochondrial function in the mdx mice, which supports that modulating PPARδ may be therapeutically beneficial in DMD patients.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29458111     DOI: 10.1016/j.mito.2018.02.006

Source DB:  PubMed          Journal:  Mitochondrion        ISSN: 1567-7249            Impact factor:   4.160


  5 in total

1.  Single- and multiple-dose safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ASP0367, or bocidelpar sulfate, a novel modulator of peroxisome proliferator-activated receptor delta in healthy adults: Results from a phase 1 study.

Authors:  Mototsugu Ito; Sitra Tauscher-Wisniewski; Ronald A Smulders; Tomasz Wojtkowski; Akihiro Yamada; Akira Koibuchi; Tolga Uz; Gerard J Marek; Ronald D Goldwater
Journal:  Muscle Nerve       Date:  2021-10-28       Impact factor: 3.852

Review 2.  Disease-associated metabolic alterations that impact satellite cells and muscle regeneration: perspectives and therapeutic outlook.

Authors:  Josiane Joseph; Jason D Doles
Journal:  Nutr Metab (Lond)       Date:  2021-03-25       Impact factor: 4.169

3.  The Failed Clinical Story of Myostatin Inhibitors against Duchenne Muscular Dystrophy: Exploring the Biology behind the Battle.

Authors:  Emma Rybalka; Cara A Timpani; Danielle A Debruin; Ryan M Bagaric; Dean G Campelj; Alan Hayes
Journal:  Cells       Date:  2020-12-10       Impact factor: 6.600

4.  Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice.

Authors:  Michael Ziemba; Molly Barkhouse; Kitipong Uaesoontrachoon; Mamta Giri; Yetrib Hathout; Utkarsh J Dang; Heather Gordish-Dressman; Kanneboyina Nagaraju; Eric P Hoffman
Journal:  PLoS One       Date:  2021-02-22       Impact factor: 3.240

5.  Mutation-independent Proteomic Signatures of Pathological Progression in Murine Models of Duchenne Muscular Dystrophy.

Authors:  Tirsa L E van Westering; Henrik J Johansson; Britt Hanson; Anna M L Coenen-Stass; Yulia Lomonosova; Jun Tanihata; Norio Motohashi; Toshifumi Yokota; Shin'ichi Takeda; Janne Lehtiö; Matthew J A Wood; Samir El Andaloussi; Yoshitsugu Aoki; Thomas C Roberts
Journal:  Mol Cell Proteomics       Date:  2020-09-29       Impact factor: 5.911

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.